Hancock Whitney Corp Lowers Position in Johnson & Johnson (NYSE:JNJ)

Hancock Whitney Corp trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 3.0% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 51,628 shares of the company’s stock after selling 1,612 shares during the quarter. Hancock Whitney Corp’s holdings in Johnson & Johnson were worth $7,546,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Gilbert & Cook Inc. grew its stake in Johnson & Johnson by 3.3% during the fourth quarter. Gilbert & Cook Inc. now owns 9,111 shares of the company’s stock worth $1,428,000 after buying an additional 288 shares during the period. 9258 Wealth Management LLC grew its stake in Johnson & Johnson by 2.1% during the fourth quarter. 9258 Wealth Management LLC now owns 22,034 shares of the company’s stock worth $3,454,000 after buying an additional 443 shares during the period. Gryphon Financial Partners LLC boosted its stake in shares of Johnson & Johnson by 66.3% in the fourth quarter. Gryphon Financial Partners LLC now owns 14,245 shares of the company’s stock valued at $2,244,000 after purchasing an additional 5,680 shares during the period. TrinityPoint Wealth LLC boosted its stake in shares of Johnson & Johnson by 1.9% in the fourth quarter. TrinityPoint Wealth LLC now owns 36,777 shares of the company’s stock valued at $5,764,000 after purchasing an additional 700 shares during the period. Finally, Pzena Investment Management LLC boosted its stake in shares of Johnson & Johnson by 0.6% in the fourth quarter. Pzena Investment Management LLC now owns 637,662 shares of the company’s stock valued at $99,947,000 after purchasing an additional 3,645 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Sanford C. Bernstein upped their target price on shares of Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. The Goldman Sachs Group decreased their target price on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. Morgan Stanley upped their target price on shares of Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a research note on Thursday, July 18th. TD Securities cut their price target on shares of Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a report on Friday. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $173.21.

Johnson & Johnson Stock Down 0.4 %

Johnson & Johnson stock opened at $164.11 on Friday. The company has a 50-day simple moving average of $161.30 and a 200-day simple moving average of $154.20. The firm has a market capitalization of $394.96 billion, a P/E ratio of 10.23, a P/E/G ratio of 2.71 and a beta of 0.53. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping the consensus estimate of $2.71 by $0.11. The business had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company’s quarterly revenue was up 4.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.80 earnings per share. As a group, equities analysts expect that Johnson & Johnson will post 10.02 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were given a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 annualized dividend and a dividend yield of 3.02%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.